Skip to main content

Incannex appoints principal investigators for pivotal IHL-42X trial

--News Direct--

Incannex Healthcare Ltd (ASX:IHL, NASDAQ: IXHL) CEO Joel Latham tells Proactive the company has appointed two highly experienced lead principal investigators for its Phase 2/3 clinical trial of IHL-42X, a treatment for obstructive sleep apnoea (OSA). The investigators, Dr John D Hudson of FutureSearch Trials of Neurology in Austin, Texas, and Dr Russell Rosenberg of Neurotrials Research Inc in Atlanta, Georgia, will play a crucial role overseeing the first clinical trial sites, handling submissions to the FDA and obtaining ethics approval from Institutional Review Boards.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

Jonathan@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/incannex-appoints-principal-investigators-for-pivotal-ihl-42x-trial-508961464

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.46
+3.19 (1.55%)
AAPL  272.26
+6.08 (2.28%)
AMD  213.67
+17.07 (8.68%)
BAC  50.45
-0.62 (-1.22%)
GOOG  310.81
-0.88 (-0.28%)
META  639.85
+2.60 (0.41%)
MSFT  389.03
+4.56 (1.19%)
NVDA  193.07
+1.52 (0.79%)
ORCL  145.78
+4.47 (3.16%)
TSLA  409.42
+9.59 (2.40%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.